Delivery Order SPE2DR25D2206-SPE2DR26F9FV4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $28,501.50 to AmerisourceBergen Drug Corp for the supply of Citalopram HBr 40 mg tablets in quantities of 500 units. This firm fixed price delivery order, issued on September 25, 2025, represents a non-competitive award under an existing contract vehicle and is scheduled for ultimate completion by September 26, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Citalopram HBr 10 mg tablets (500 count) valued at $46,580.81 under a firm fixed-price contract. This competitively awarded delivery order, with no set-aside designation, was issued on September 23, 2025, with an ultimate completion date of September 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,959.19 to AmerisourceBergen Drug Corp for the supply of Citalopram HBr 40 mg tablets (500 count) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreements with the agency. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $17,210.57 to AmerisourceBergen Drug Corp for the supply of Citalopram HBR 40 mg tablets (500 count) on September 11, 2025, with an ultimate completion date of September 12, 2025. This competitively awarded, firm fixed price delivery order carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's...
- The Defense Logistics Agency awarded a $16,446.23 delivery order to AmerisourceBergen Drug Corp for the supply of Citalopram HBR 40 mg tablets (100-count) on December 15, 2025, with completion scheduled for December 16, 2025. This non-set-aside contract utilizes firm fixed price terms and represents a competitively awarded delivery order under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical. Performance will be executed from the contractor's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,329.50 to AmerisourceBergen Drug Corp for the supply of Citalopram HBR 40 mg tablets (500 count) on September 9, 2025, with an ultimate completion date of September 10, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and identifies the place of performance as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Citalopram HBR 40 mg tablets in a quantity of 500 units. This is a firm fixed-price delivery order with a ceiling value of $6,230.19 and an ultimate completion date of December 1, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $6,068.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 tablets of Citalopram HBR 40 mg, with an ultimate completion date of December 11, 2025. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio. The place of performance is the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,494.09 to AmerisourceBergen Drug Corp for the supply of Citalopram HBr 20 mg tablets (500 count) on October 29, 2025, with an ultimate completion date of October 30, 2025. This contract was awarded on a firm fixed price basis with no set-aside designation, indicating open competition among qualified vendors. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a $16,222.46 delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Citalopram HBr 40 mg tablets (100-count units). This is a firm fixed-price, non-set-aside contract with a completion date of June 9, 2025, and performance to be executed from the vendor's location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs. This delivery order is issued...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9FV4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Citalopram HBR 40 mg tablets in quantities of 100 units, valued at $2,435.55. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by December 16, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive pharmaceutical supply vehicle enabling AmerisourceBergen to deliver a broad range of generic and brand-name medications, vaccines, and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen has demonstrated consistent capability to fulfill DLA requirements through open competition across multiple therapeutic domains, including neurological treatments, pain management pharmaceuticals, and specialty medications that support the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 12/14/25 |